UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 or 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~August 21,~~October 25, 2023

Rennova Health, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-35141		68-0370244
(Commission File Number)		(I.R.S. Employer Identification No.)

400 S. Australian Avenue, Suite 800, West Palm Beach, Florida		33401
(Address of Principal Executive Offices)		(Zip Code)

(561) 855-1626

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered under Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
None		None		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7 1.01. ~~Regulation~~Entry FDinto ~~Disclosure~~a Material Definitive Agreement

On ~~August~~October 2125, 2023, Rennova Health, Inc. (the “Company”) entered ~~issued~~into aan ~~press~~Amendment ~~release~~and ~~announcing~~Waiver ~~that~~Agreement ~~Seamus~~(the ~~Lagan~~“Agreement”) with the holders of its Senior Secured Original Issue Discount Convertible Debentures due March 21, ~~our~~2019 ~~Chief~~(the “March 2019 Debentures”) and its Senior Secured Original Issue Discount Convertible ~~Executive~~Debentures ~~Officer~~due September 19, ~~would~~2019 be(collectively ~~interviewed~~with onthe ~~Uptick~~March ~~Newswire’s~~2019 ~~“Stock~~Debentures, ~~Day~~the “Debentures”). ~~podcast~~As ~~with~~of ~~Kevin~~June ~~Davis~~30, 2023, there were outstanding $8,222,240 principal amount of Debentures (including mandatory default amounts, if any) and $6,192,700 in accrued interest. Under Athe ~~copy~~Agreement, all defaults under the Debentures were waived and the maturity date of the Debentures was extended to December 31, ~~press~~2025. ~~release~~Certain isother ~~attached~~amendments ~~hereto~~were asalso ~~Exhibit~~made 99in the terms of the Debentures.1 ~~and~~As a ~~transcript~~result of the ~~interview~~Agreement, isthe ~~attached~~Company ~~hereto~~does asnot expect ~~Exhibit~~to 99recognize default interest in future periods, subject to remaining in compliance with covenants and other obligations.2.

The ~~information~~foregoing ~~furnished~~description ~~pursuant to this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes~~ of ~~Section 18 of~~ the ~~Securities~~Agreement ~~Exchange~~does ~~Act~~not ofpurport ~~1934, as amended (the “Exchange Act”), or otherwise subject~~ to ~~the~~be ~~liabilities of~~complete ~~that section,~~ and ~~shall~~is ~~not~~qualified bein ~~deemed~~its toentirety ~~be incorporated~~ by reference ~~into~~to ~~any filing of~~ the ~~Company~~Agreement, a ~~under~~form ~~the~~of ~~Securities~~which ~~Act~~is offiled ~~1933,~~ as ~~amended,~~Exhibit or10.1 ~~the~~to ~~Exchange~~this ~~Act,~~Current ~~except~~Report ason ~~shall~~Form be8-K ~~expressly~~and ~~set~~is ~~forth~~incorporated herein by ~~specific~~ reference ~~in such filing~~.

Item 9.01. Financial Statements and Exhibits

(d)

Exhibits

Exhibit No.		Exhibit Description
99.1		Press Release dated August 21, 2023
10.1		Form of Amendment and Waiver Agreement, dated as of October 25, 2023, among Rennova Health, Inc., Sabby Healthcare Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd.
99.2		Transcript of Interview of Seamus Lagan
99.1		Press Release dated October 25, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 21, 2023	RENNOVA HEALTH, INC.
Date: October 31, 2023	RENNOVA HEALTH, INC.
	By:	/s/ Seamus Lagan
		Seamus Lagan
		Chief Executive Officer
		(principal executive officer)

Filing Compare · Rennova Health, Inc.